These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 19954278

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
    Sand PK, Davila GW, Lucente VR, Thomas H, Caramelli KE, Hoel G.
    Am J Obstet Gynecol; 2012 Feb; 206(2):168.e1-6. PubMed ID: 21963104
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
    Ho C.
    Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
    [Abstract] [Full Text] [Related]

  • 8. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A, Mallina R, Dowson C, Larner T, Khan MS.
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [Abstract] [Full Text] [Related]

  • 9. Oxybutynin gel for the treatment of overactive bladder.
    Gomelsky A, Dmochowski RR.
    Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
    Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan E, Hoel G.
    J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
    [Abstract] [Full Text] [Related]

  • 15. Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.
    Saltzstein L.
    Urol Nurs; 2005 Aug; 25(4):260-2. PubMed ID: 16225342
    [Abstract] [Full Text] [Related]

  • 16. Application drying time for oxybutynin chloride topical gel.
    Newman DK, Olsen SM, Dahl NV.
    Urol Nurs; 2012 Aug; 32(5):265-9. PubMed ID: 23472531
    [Abstract] [Full Text] [Related]

  • 17. Transdermal oxybutynin: a new treatment for overactive bladder.
    Davila GW.
    Expert Opin Pharmacother; 2003 Dec; 4(12):2315-24. PubMed ID: 14640930
    [Abstract] [Full Text] [Related]

  • 18. The evolution of transdermal therapy for overactive bladder.
    Sand PK.
    Curr Urol Rep; 2009 Sep; 10(5):338-41. PubMed ID: 19709479
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?
    MacDiarmid SA.
    BJU Int; 2007 Jun; 99 Suppl 3():8-12. PubMed ID: 17488367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.